Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend.
Articles on Biosimilars
Displaying all articles
Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here’s where they come from and how they work.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Top contributors
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Fellow, Australian National University
-
Doctoral Student in Biochemistry, University of Washington
-
Professor of Public Health, La Trobe University
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Honorary Associate Professor; economics of patents, geographical indications and other "IP"; trade treaties, Australian National University